TY  - JOUR
AU  - Shapiro, Noah L
AU  - Jones, Peter Simon
AU  - Mak, Elijah
AU  - Tsvetanov, Kamen A
AU  - Goddard, Julia
AU  - Vontobel, Davi S
AU  - Durcan, Robert
AU  - Chouliaras, Leonidas
AU  - Fryer, Tim
AU  - Hong, Young T
AU  - Aigbirhio, Franklin
AU  - Heslegrave, Amanda
AU  - Franzmeier, Nicolai
AU  - Brendel, Matthias
AU  - Zetterberg, Henrik
AU  - O'Brien, John T
AU  - Rowe, James B
AU  - Malpetti, Maura
TI  - Inflammation PET and plasma neurofilament light predict survival in people with progressive supranuclear palsy.
JO  - Brain communications
VL  - 7
IS  - 6
SN  - 2632-1297
CY  - [Oxford]
PB  - Oxford University Press
M1  - DZNE-2025-01418
SP  - fcaf467
PY  - 2025
AB  - Progressive supranuclear palsy (PSP) is a primary tauopathy characterized by atrophy and neuroinflammation of the brainstem, the basal ganglia and, to a lesser degree, the cortex. This study investigates the association of regional atrophy (structural MRI), neuroinflammation ([11C]-PK11195 PET), peripheral markers of neurodegeneration [plasma neurofilament light chain (NfL)] and clinical severity [PSP rating scale (PSPRS)] with survival in people with PSP. Fifty-nine people with PSP underwent longitudinal structural MRI, surviving on average 3.2 years from the first scan (MRI cohort). Sixteen participants (PET cohort) within this cohort underwent cross-sectional [11C]-PK11195 PET and blood sampling for plasma NfL. We applied modality-specific principal component analyses on imaging data and ran partial correlations, multivariate regressions and Bayesian models to evaluate the association between survival and imaging patterns, clinical severity and plasma NfL. In the PET cohort, higher levels of localized inflammation in subcortical regions [rho = -0.49, P = 0.02, Bayes factor (BF) = 8.07] and plasma NfL (rho = -0.57, P = 0.01, BF = 4.63) were associated with shorter survival, while PSPRS scores were not significant predictors of survival. Subcortical atrophy was associated with shorter survival in the larger cohort (r = -0.38, P = 0.001; β = -0.66, P = 0.001). Spearman's correlations, multivariate regressions and Bayesian models converged to the same results. Regional subcortical atrophy is a robust biomarker associated with survival in people with PSP that can be utilized in large-scale clinical trials. Translocator protein (TSPO) PET and plasma NfL offer promising complementary markers for smaller-scale trials, where they may prove more sensitive than clinical scores or structural MRI alone. By linking neuroinflammation to survival, our results also highlight immunotherapy as a promising avenue for disease-modifying treatment in PSP.
KW  - PET NfL (Other)
KW  - neuroinflammation (Other)
KW  - progressive supranuclear palsy (Other)
KW  - survival (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41416250
C2  - pmc:PMC12709281
DO  - DOI:10.1093/braincomms/fcaf467
UR  - https://pub.dzne.de/record/282966
ER  -